COPD: The First 90 Days — Body Handbook

Breathing · §10

COPD: The First 90 Days

The first ninety days after a COPD diagnosis are the part you control. Most people treat it as maintenance: collect an inhaler, keep smoking, wait for the next winter chest infection. But five things bend the next decade, and they fit inside three months: confirm it with a real breathing test, take the blood test nearly every clinic forgets, quit with drug help, match the inhaler to your risk, finish rehab. Do them and the breath you keep at sixty looks closer to a never-smoker's.

Condition Evidence Strong Chapter Breathing

A cough and a chest X-ray is not a diagnosis. COPD is locked in by spirometry: you blow into a tube before and after a bronchodilator puff, and a ratio under 0.7 afterward confirms it ¹. Without it you might have asthma or heart failure being misread, and their inhalers do not fit COPD.

Three numbers in the same visit decide the rest. A one-time blood test for alpha-1 antitrypsin, the inherited deficiency missed in about ninety-five percent of new patients ² ³. A blood eosinophil count: above 300 per microlitre marks the patient a steroid inhaler helps, below 100 the one it harms ⁴. And an honest flare-up tally for the year.

The cost of drifting is slow, not dramatic. People who keep smoking after diagnosis lose lung capacity about twice as fast: 62 millilitres a year against 28 ⁵, and roughly fifteen percent higher mortality in the years that follow ⁶. A hospital admission for a flare runs a one-year mortality near twenty-two percent when rehab is skipped on discharge ⁷ ⁸. The damage already done does not return; these ninety days change the rate of further loss.

Five strands, all begun in month one, running by week twelve.

Confirm (week 1–2). Post-bronchodilator spirometry. Blood eosinophil count. A serum alpha-1 antitrypsin level. A CAT or mMRC symptom score. A flare-up tally for the past year.
Quit with help (week 1–2). Ask for varenicline plus behavioural support — a quitline, group, or app; patches and lozenges if varenicline is off the table. Pick a quit day inside two weeks. Cutting down does not protect the lung; only stopping does ⁵ ⁹.
Match the inhaler (week 2–6). Start with a long-acting bronchodilator (LAMA); add a LABA for higher symptoms; add a steroid inhaler only if eosinophils reach 300 or flares are frequent ¹.
Vaccinate (week 2–6). Flu, pneumococcal, COVID, and RSV at sixty or older ¹⁰ ¹¹.
Pulmonary rehab (week 4–12). Get the referral by week four. It does more for daily breathing than any inhaler and cuts admissions after a flare ¹² ⁸.
Recheck (week 12). Repeat spirometry, have your inhaler technique corrected, write a flare-up action plan.

What you feel, and when.

First month: the morning cough quiets; the first stairs feel different by week two.
Three months: rehab graduates walk further before stopping, and the low-grade depression that trails a diagnosis lifts as competence returns ¹².
First year: the loss rate has roughly halved, with a measurable rebound in the months after quitting ¹³.
First year: the loss rate has roughly halved, with a measurable rebound in the months after quitting ¹³.

The fine print — when to skip it, and what people get wrong

A steroid inhaler is not the default: below 100 eosinophils and without frequent flares it adds pneumonia risk for no gain ¹⁴ ¹⁵. Varenicline is off the table in pregnancy; nicotine replacement is the fallback.

Cutting cigarettes in half protects nothing; only stopping does ⁵. The steroid inhaler is an add-on, not the main COPD drug — the bronchodilator is ¹⁴. Rehab helps most while you can still train hard, so earlier beats later ¹⁶.

Where it falls apart: diagnosis made off an X-ray with no spirometry; the alpha-1 test never ordered ²; "try to quit" as the whole plan, when drugs plus support roughly triple the quit rate ¹⁷; rehab mentioned but never referred; inhaler technique never watched.

References

1GOLD (2025). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease (2025 Report). link
2American Thoracic Society, European Respiratory Society (2003). American Thoracic Society/European Respiratory Society Statement: Standards for the Diagnosis and Management of Individuals with Alpha-1 Antitrypsin Deficiency. American Journal of Respiratory and Critical Care Medicine. link
3Blanco I, Bueno P, Diego I, et al. (2017). Alpha-1 antitrypsin Pi*Z gene frequency and Pi*ZZ genotype numbers worldwide: an update. International Journal of COPD. link
4Pascoe S, Barnes N, Brusselle G, et al. (2019). Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial. The Lancet Respiratory Medicine. link
5Anthonisen NR, Connett JE, Kiley JP, et al. (1994). Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1: the Lung Health Study. JAMA. link
6Anthonisen NR, Skeans MA, Wise RA, et al. (2005). The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Annals of Internal Medicine. link
7Suissa S, Dell'Aniello S, Ernst P (2012). Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality. Thorax. link
8Lindenauer PK, Stefan MS, Pekow PS, et al. (2020). Association between initiation of pulmonary rehabilitation after hospitalization for COPD and 1-year survival among Medicare beneficiaries. JAMA. link
9Leone FT, Zhang Y, Evers-Casey S, et al. (2020). Initiating Pharmacologic Treatment in Tobacco-Dependent Adults: An Official American Thoracic Society Clinical Practice Guideline. American Journal of Respiratory and Critical Care Medicine. link
10Kopsaftis Z, Wood-Baker R, Poole P (2018). Influenza vaccine for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews. link
11Walters JA, Tang JN, Poole P, Wood-Baker R (2017). Pneumococcal vaccines for preventing pneumonia in chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews. link
12McCarthy B, Casey D, Devane D, et al. (2015). Pulmonary rehabilitation for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews. link
13Scanlon PD, Connett JE, Waller LA, et al. (2000). Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease: the Lung Health Study. American Journal of Respiratory and Critical Care Medicine. link
14Calverley PMA, Anderson JA, Celli B, et al. (2007). Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease (TORCH). New England Journal of Medicine. link
15Suissa S, Dell'Aniello S, Ernst P (2018). Comparative effects of LAMA-LABA-ICS vs LAMA-LABA for COPD: cohort study in real-world clinical practice. Chest. link
16Spruit MA, Singh SJ, Garvey C, et al. (2013). An official American Thoracic Society/European Respiratory Society statement: key concepts and advances in pulmonary rehabilitation. American Journal of Respiratory and Critical Care Medicine. link
17van Eerd EAM, van der Meer RM, van Schayck OCP, Kotz D (2016). Smoking cessation for people with chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews. link

Related in the handbook (14)

Helped by

— Vaccines are one of the five first-90-days jobs — a chest infection is what tips COPD downhill.
— Getting inhaler technique right is part of the first 90 days — the drug only works if it reaches the lungs.
— NAC is a low-risk add-on worth raising for chronic-bronchitis-type COPD; it can reduce exacerbations over a season.
— Quitting cigarettes is the single biggest lever in COPD, and a full switch to vaping is one route there.

Worsened by

— Scented candles add soot and irritant fumes to your air; with COPD they're an easy household trigger to remove.
— Aerosol cleaning sprays and fragrance solvents irritate damaged airways; switching to cloth and soap removes a daily trigger.
— Quitting smoking, with real drug help, is step one of the COPD playbook — nothing else matters as much.

— COPD is the other big inhaler-treated airway disease — the pathways differ, so confirm which you have.
— The blood test clinics forget checks for alpha-1 antitrypsin deficiency — an inherited cause of COPD worth ruling out once.
— The same long-term smokers eligible for lung screening are the ones who should also get checked for COPD.
— If you monitor your oxygen at home for a lung condition, the skin-tone bias matters most exactly when you're sick and the number is borderline.
— A chronic lung condition like COPD moves you into the eligible group at 50–74 — and makes RSV more dangerous if you catch it.
— COPD plus sleep apnea, the 'overlap syndrome', hits your oxygen harder at night. Worth testing for if you wake unrefreshed.
— A slice of COPD is driven by Type 2 (eosinophilic) inflammation — that subgroup now has a biologic option.